LGI-1 antibody associated limbic encephalitis in a Brazilian woman with faciobrachial dystonic seizures

Beatriz Anjos GV1, Alberto Phang CP1, Fabiano Ferreira DA2, Livia Almeida D1 and Romana Höftberger4

1Department of Medical Clinics, Ipiranga Hospital, São Paulo, Brazil
2Department of Neurology and Neurosurgery, Federal University of Sao Paulo, Brazil
3Affiliated Professor, Department of Neurology and Neurosurgery, Federal University of Sao Paulo, Brazil
4Medizinische Universität Wien, Austria

Abstract
The most characteristic autoimmune encephalopathy syndrome is limbic encephalitis, frequently featuring confusion, memory impairment, psychiatric symptoms and seizures. LGI-1 antibody-associated encephalitis is frequently preceded by a highly characteristic seizure semiology termed faciobrachial dystonic seizure.

Introduction
Autoimmune encephalopathy syndromes associated with autoantibodies to the voltage-gated potassium channel (VGKC) or its complex proteins were first described in 2001. In 2010, the receptor-associated proteins like contactin-associated protein-like 2 (CASPR2) and leucine-rich glioma inactivated 1 (LGII1) were identified as the antigenic targets in most cases of VGKC antibody-associated syndromes [1-3].

Autoantibodies against the extracellular domains of the VGKC complex protein, LGI1, and CASPR2 have been described in patients with limbic encephalitis (LE), neumyotonia, and Morvan syndrome. In patients suffering from LE, LGI1 is the most commonly targeted VGKC-complex protein. It has been shown that identifying LGI1 antibody has a better sensitivity and specificity than VGKC-complex antibody testing in providing a diagnosis and rationale immunotherapy for autoimmune diseases. Amnesia, confusion, and seizure are the main symptoms of LGI1-related LE. Recently, another distinctive symptom involving brief, very frequent episodes that typically involve dystonic posturing of the hemiface and ipsilateral arm (faciobrachial dystonic seizures, FBDS) has been described and is currently viewed as pathognomonic for the presence of LGI1 antibodies [4-6].

Case history
A 43-year old female presented with a 6-month medical history of severe anxiety symptoms which progressed to hallucinations. Antipsychotic medication (risperidone 1mg/day) was administrated to control hallucinations 2 months prior to admission when the patient started presenting sporadic generalized tonic-clonic seizures and cognitive decline (memory impairment and confusion). The patient became worse 1 week prior to admission and was admitted to the emergency service with generalized tonic-clonic seizure. Her Glasgow coma scale score was 7 (E2V1M4), and the seizure persisted. She was intubated and placed on respiratory support. Antiepileptic drugs (1500mg of fosphenytoin and 20mg of diazepam) were administrated and midazolam was continued after intubation. Her neurologic examination was unremarkable except for her reduced level of consciousness. A computed tomography (CT) scan of the head didn’t show abnormalities. Her complete blood count and electrolytes revealed hyponatremia (120mmol/L). A lumbar puncture was performed and the cerebrospinal fluid analysis (proteins, glucose, red and white blood cells, bacteria) were normal. The patient was submitted to thoracic, abdominal and pelvic CT scans which were unremarkable. Infectious tests (HIV, HCV, HBC, HSV-1,HSV-2, VZY, CMV), rheumatologic disease studies (RF,ANA, complement test, c-ANCA, p-ANCA), and tumor markers (CEA,CA 19-9, anti-TPO) were normal. The patient was extubated after generalized tonic-clonic seizures ceased but continued to present confusional state and several episodes of dystonic posturing of the face and right arm (Figures 1 and 2). Magnetic resonance imaging documented bilateral hippocampal high intensity signal on T2/Flair weighted images (Figure 3). EEG recording revealed disorganized slow activities with preserved reactivity. Serum and cerebrospinal fluid was sent to Klinisches Institut für Neurologie in Wien to analyze the presence of anti-neuronal antibodies. Screening on a tissue-based assay for surface receptor antibodies (avidin-biotin-peroxidase technique; rat brain) showed a specific neuropil staining and a subsequent performed cell-based assay (IIFT; Euroimmun) was positive for anti-LGI1 antibodies with the antibody titer in serum of 1:12800 (primary dilution 1:200) and the antibody titer in CSF of 1:256 (primary dilution 1:2). A tissue-based assay (avidin-biotin-peroxidase technique; rat cerebellum) for onconeuronal antibodies (Hu, Yo, Ri, Tr, CV2, amphiphysin, Ma1/2), PKCgamma, CARPVIII, ARHGAP26, tumor-associated antibodies (SOX1, ZIC4) and non-tumor-associated antibodies (GAD65, AK5, Homer3) was negative. The patient was treated with immunotherapy. First, she received intravenous...
methylprednisolone pulsotherapy (1g/d for 5 days) without significant improvement. After the first pulsotherapy, she received intravenous immunoglobulin (IVIG- 0.4g/Kg/d for 5 days), had a partial improvement and was discharged with reduced seizure episodes, more awake but with significant cognitive impairment. After 1 month she was readmitted to the hospital because she was very somnolent and the frequency of faciobraquial dystonic seizures had increased. She received intravenous cyclophosphamide 500 mg/m²/day, and more alert with fewer FBDS, was discharged to outpatient follow-up.

References


Copyright: ©2018 Beatriz Anjos GV. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.